Open access peer-reviewed Edited Volume

Antidepressants - Recent Advances, Applications and Translational Models

Berend Olivier

Utrecht University

An academic and industrial investigator involved in basal research, drug discovery, and development of potential psychiatric drugs, covering depression, anxiety, OCD, schizophrenia, and sexual dysfunctions.

Covering

Epidemiology Development New Developments Measurement Scales Mechanisms New Molecules New Therapeutic Areas Brain Structures Genetic Models Pharmacological Models Genomics Neuropsychiatry

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Major depression is as old as mankind. Treatment of depression has been and still is a major challenge notwithstanding the rapid rise in our knowledge of the brain and its (dysfunction)functions. Since halfway last century, research into putative antidepressants has emerged, leading to early antidepressants like monoamine oxidase inhibitors and tricyclic antidepressants. These early drugs have antidepressant effects but only in a limited part of the depressed population and suffered from serious side effects and slow onset of action. The next generation builds on the underlying mechanisms of action of the early antidepressants and, although having fewer side effects, still had no improved antidepressant profile. Although since then several other mechanisms have been investigated and tried as therapeutic drugs, no real breakthroughs have been obtained. In the last decade, new developments in glutaminergic mechanisms have suggested that this new area might bring new and better antidepressants. Ketamine and associated molecules might create a new way of treating severe depression: fast onset of action and activity in treatment-resistant depression.

The present book will try to capture several aspects of the ongoing search for new and better antidepressants. New developments in molecules, brain (dys)function, (epilepsy)genetics, genomics, the onset of action, brain stimulation, and new treatment strategies are at present relevant research themes. The book will try to capture the present situation by implementing both medical, biological, chemical, and genetic aspects in an endeavor to represent the present state of the art.

Publishing process

Book initiated and editor appointed

Date completed: October 12th 2021

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: November 9th 2021

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: January 8th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: March 29th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: May 28th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Berend Olivier

Utrecht University

Berend Olivier studied biology and got his PhD degree in Neurobiology at Groningen University. He worked for 22 years at Solvay Pharmaceuticals leading active research and development of psychoactive drugs, including antidepressants, antipsychotics and anxiolytics and a new group of drugs, serenics, aiming for reduction of pathological aggression. He was involved in research and development around fluvoxamine, a marketed SSRI antidepressant, anxiolytic and anti-OCD medicine. In 1999, he worked for 2 years in New York to set up a biotech start-up, PsychoGenics Inc., developing animal psychiatric and neurological (genetic) models in order to screen and find new psychoactive molecules. From 1992–2014, he was a professor of CNS Pharmacology at Utrecht University, performing research on animal models, brain mechanisms and pharmacology of psychiatric disorders.

View profile

Book chapters authored 4

Books edited 2

Introducing your Author Service Manager

Ms. Zrinka Tomicic

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire